"Deceptive Advertising!" Claims Novo Nordisk in Explosive New GLP-1 Lawsuit Against Eli Lilly. Here's What That Means for Both Stocks.

Published July 21, 2026 · Category: Finance

Overview

The GLP-1 market has been hot for a long time, but things are even more heated behind the scenes. Danish healthcare company Novo Nordisk (NYSE:NVO) and massive U.S. drugmaker Eli Lilly (NYSE:LLY) have been battling for supremacy in the massive U.S. GLP-1 market.

And as of Tuesday morning, the feud has officially landed in the courtroom, as Novo Nordisk announced it had filed a lawsuit against its rival in federal court.

Details

Novo, the maker of GLP-1s Ozempic and Wegovy, claims that Eli Lilly’s ads for its competing GLP-1 brands, Mounjaro and Zepbound, rely on “deceptive advertising” that has caused “widespread confusion” in the marketplace.

Continue reading

Source

Originally published at www.fool.com.

Related Articles

• The Fed rang the alarm about Anthropic's Mythos AI model — but had to go months without it
• What This Synaptics Insider Filing Signals to Long-Term Investors With the Stock Up 72% in a Year
• Super Micro’s stock soars as its margins unexpectedly double